A Survey of Preclinical Studies Evaluating Nanoparticle-Based Vaccines Against Non-Viral Sexually Transmitted Infections

Abisola Abisoye-Ogunniyan, Isabella M. Carrano, Dina R. Weilhammer, Sean F. Gilmore, Nicholas O. Fischer, Sukumar Pal, Luis M. de la Maza, Matthew A. Coleman, Amy Rasley

Research output: Contribution to journalReview articlepeer-review

Abstract

A worldwide estimate of over one million STIs are acquired daily and there is a desperate need for effective preventive as well as therapeutic measures to curtail this global health burden. Vaccines have been the most effective means for the control and potential eradication of infectious diseases; however, the development of vaccines against STIs has been a daunting task requiring extensive research for the development of safe and efficacious formulations. Nanoparticle-based vaccines represent a promising platform as they offer benefits such as targeted antigen presentation and delivery, co-localized antigen-adjuvant combinations for enhanced immunogenicity, and can be designed to be biologically inert. Here we discuss promising types of nanoparticles along with outcomes from nanoparticle-based vaccine preclinical studies against non-viral STIs including chlamydia, syphilis, gonorrhea, and recommendations for future nanoparticle-based vaccines against STIs.

Original languageEnglish (US)
Article number768461
JournalFrontiers in Pharmacology
Volume12
DOIs
StatePublished - Nov 24 2021
Externally publishedYes

Keywords

  • chlamydia
  • delivery platforms
  • gonorrhea
  • immunogenicity
  • nanoparticles
  • STIs
  • syphilis
  • vaccines

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'A Survey of Preclinical Studies Evaluating Nanoparticle-Based Vaccines Against Non-Viral Sexually Transmitted Infections'. Together they form a unique fingerprint.

Cite this